Report copyright - Clinical Policy: Evolocumab (Repatha)...a) ≥ 190 mg/dL for genetically mediated primary hyperlipidemias; b) ≥ 220 mg/dL for non-genetically mediated primary hyperlipidemias; b
Please pass captcha verification before submit form
Please pass captcha verification before submit form